3) suggested that some individuals with HER2-negative tumors can benefit from Herceptin. In these trials, which compared chemotherapy alone with chemotherapy plus Herceptin, only women who were ...

北京大学深圳医院农巧红教授、余少康医生分享一例 T-DXd 治疗两线内分泌经治 HR+/HER2 低表达转移性乳腺癌的诊疗全过程。案例概述41 岁女性患者，初诊左侧乳腺浸润性导管癌 cT3NxM0，IIIC 期，LuminalA 型（HER2 IHC ...

In the absence of head-to-head studies, oncologists are looking across pivotal trials and are encouraged by Itovebi's safety and efficacy versus Piqray.

In this trial, alisertib will be assessed in conjunction with endocrine therapy for treating individuals having hormone ...